In vitro immune modulation by antibodies coupled to tumour cells.
Modification of autologous tumour cells to express the immune costimulator B7.1 is a potential strategy for immunotherapy of cancer. Previously, this has involved introduction of genetic material into cells, in vitro culture, and confirmation of the protein product on the cell surface. This is possi...
主要な著者: | Darling, D, Galea-Lauri, J, Gäken, J, Towner, P, Kuiper, M, Hollingsworth, S, Hirst, W, Barnard, A, Buggins, A, Mufti, G, Farzaneh, F |
---|---|
フォーマット: | Journal article |
言語: | English |
出版事項: |
1997
|
類似資料
-
Induction of tumour rejection by B7.1 and IL-2 expressing tumour cells
著者:: Gaken, J, 等
出版事項: (1997) -
Induction of tumour rejection by autologous and allogeneic tumour cells expressing B7.1 and IL-2.
著者:: Hirst, W, 等
出版事項: (1996) -
Irradiated NC adenocarcinoma cells transduced with both B7.1 and interleukin-2 induce CD4+-mediated rejection of established tumors.
著者:: Gaken, J, 等
出版事項: (1997) -
Tumour cells expressing B7.1 costimulatory molecule: Are these better targets for NK cells?
著者:: GaleaLauri, J, 等
出版事項: (1996) -
An immune edited tumour versus a tumour edited immune system: Prospects for immune therapy of acute myeloid leukaemia.
著者:: Chan, L, 等
出版事項: (2006)